SOPHiA GENETICS Announced The Global Launch Of MSK-impact Powered With Sophia DDM From The Association For Molecular Pathology Annual Meeting
Morgan Stanley Maintains Sophia Genetics(SOPH.US) With Hold Rating, Maintains Target Price $5
Morgan Stanley Sticks to Its Hold Rating for SOPHiA GENETICS (SOPH)
Earnings Call: SOPHiA GENETICS Reported A16% Year-over-year Increase in Analysis Volume
Sophia Genetics Shares Are Trading Lower. The Stock May Be Moving on Continued Weakness Following a Q3 Earnings Miss on Tuesday.
SOPHiA GENETICS SA (SOPH) Q3 2024 Earnings Call Transcript Summary